

**RECOMBINANT PYRUVATE PHOSPHATE
DOKINASE (rPPDK): DEVELOPMENT OF
ANTIBODY AND ANTIGEN RAPID DIPSTICK
TESTS FOR AMOEBIASIS AND
IDENTIFICATION OF POTENTIAL ANTI-
AMOEBIK COMPOUNDS**

SYAZWAN BIN SAIDIN

UNIVERSITI SAINS MALAYSIA

2017

**RECOMBINANT PYRUVATE PHOSPHATE DIKINASE
(rPPDK): DEVELOPMENT OF ANTIBODY AND
ANTIGEN RAPID DIPSTICK TESTS FOR AMOEBIASIS
AND IDENTIFICATION OF POTENTIAL ANTI-
AMOEBIC COMPOUNDS**

by

SYAZWAN BIN SAIDIN

**Thesis submitted in fulfillment of the requirements
for the degree of
Doctor of Philosophy**

May 2017

ACKNOWLEDGEMENT

In the Name of Allah, Most Gracious, Most Merciful.

Firstly, I would like to express my sincere gratitude to my Ph.D supervisor, Prof. Dr. Rahmah Noordin for the continuous support of my study and related research, for her patience, motivation, flexibility and immense knowledge. Her guidance helped me in my research and thesis writing. I would also like to thank to my co-supervisor: Dr. Nurulhasanah Othman, for her insightful comments and encouragement.

I would like to thank all members of labmates past and present: Akbar, Zohreh, Atefeh, Shaza, Hafiznur, Syahida, Ai Ying, Chang, Nad, Sam, Anizah, Kang Zhi, Jorim, Ghaya, Aline and Syuhada for the stimulating discussions, for the sleepless nights we were working together before deadlines, and for all the fun we have had in the last four years. Also I thank INFORMM's laboratory and administrative staff particularly Pn. Sabariah, Pn. Ezzati, Pn. Dyana, Pn. Azimah, Pn. Noorizan, En. Nazri, Cik Fauziah, Pn. Faizulkisnu, En. Irwan, Pn. Nurul, En. Adli, En.Omar, En. Azam, En. Azizi, Pn. Siti, Pn. Nuruljannah and En. Hafriz for their kind support. Last but not the least, I would like to thank my wife, Adibah, my lovely childrens Muhammad Luqman Al Hakim and Nur Aisyah Al Humaira, my parents and siblings for supporting me spiritually throughout the writing of this thesis and my life in general.

This study was funded by a research grant from the Malaysian Ministry of Higher Education (FRGS Grant No. 203/CIPPM/6711122). It was also partly supported by the HiCoE programme, Ministry of Higher Education. The author received financial supports through Skim Latihan Akademik Bumiputera (SLAB) from Universiti Pendidikan Sultan Idris (UPSI) and Ministry of Education, Malaysia.

TABLE OF CONTENTS

Acknowledgements.....	ii
Table of Contents.....	iii
List of Tables.....	xxi
List of Figures.....	xxv
List of Abbreviations.....	xxxiii
Abstrak.....	xxxvii
Abstract.....	xl

CHAPTER ONE: INTRODUCTION

1.1 Overview of amoebiasis.....	1
1.2 <i>Entamoeba histolytica</i>	3
1.2.1 Taxonomy.....	3
1.2.2 The biology of <i>Entamoeba histolytica</i>	3
1.2.3 Life cycle.....	6
1.3 Mode of transmission.....	9
1.4 Epidemiological studies on amoebiasis.....	10
1.4.1 Intestinal amoebiasis.....	12
1.4.2 Extraintestinal amoebiasis.....	15
1.5 Clinical manifestation of amoebiasis.....	16
1.5.1 Asymptomatic carrier.....	16

1.5.2	Intestinal amoebiasis.....	17
1.5.3	Extraintestinal amoebiasis.....	20
1.6	Pathogenesis.....	23
1.7	Immunity.....	25
1.7.1	Resistance mechanism.....	25
1.7.2	Humoral immune response.....	26
1.8	Laboratory diagnosis of amoebiasis.....	28
1.8.1	Intestinal amoebiasis.....	29
1.8.1(a)	Microscopy.....	29
1.8.1(b)	Culture.....	34
1.8.1(c)	Isoenzyme analysis.....	35
1.8.1(d)	Antigen detection test.....	36
1.8.1(e)	Molecular diagnosis.....	41
1.8.1(e)(i)	Conventional PCR.....	41
1.8.1(e)(ii)	Real-time PCR.....	43
1.8.1(e)(iii)	Loop-mediated isothermal amplification (LAMP).....	45
1.8.1(f)	Rapid diagnostic tests.....	46
1.8.2	Extraintestinal amoebiasis.....	49
1.8.2(a)	Antibody detection test.....	49
1.8.2(b)	Molecular diagnosis.....	53
1.8.2(b)(i)	Conventional PCR.....	53
1.8.2(b)(ii)	Real-time PCR.....	54

1.9	Prevention and control.....	55
1.10	Treatment of amoebiasis.....	56
1.11	Current research on the discovery of anti-amoebic compounds.....	59
1.12	Potential drug targets of pyruvate phosphate dikinase.....	62
1.13	Statement of the problems and rationale of the study.....	65
1.14	Objectives of the study.....	70

CHAPTER TWO: MATERIALS AND METHODS

2.1	Study design.....	71
2.2	Materials.....	76
2.2.1	Bacterial strains.....	76
2.2.2	Human serum samples.....	76
2.2.2(a)	Ethics statement.....	76
2.2.2(b)	Serum samples for evaluation of the diagnostic sensitivity and specificity in Western blot analysis.....	77
2.2.2(c)	Serum samples used in the development and the evaluation of lateral flow dipstick test for antibody detection.....	78
2.2.3	Stool samples used in the development and the evaluation of lateral flow dipstick test for antigen detection	78
2.2.4	New Zealand white rabbit.....	79
2.2.5	Oligonucleotide primers and probes.....	79
2.2.5(a)	Primers.....	80
2.2.5(b)	Probes.....	80

2.2.6	NCI compounds.....	82
2.2.7	<i>Entamoeba histolytica</i> strain.....	82
2.2.8	Common buffers and reagents.....	86
2.2.8(a)	10X Phosphate-buffer saline (PBS).....	86
2.2.8(b)	1X PBS.....	86
2.2.8(c)	PBS-Tween20 (PBS-T), 0.05% (v/v).....	86
2.2.8(d)	3M NaOH solution.....	86
2.2.8(e)	1M HCl solution.....	87
2.2.8(f)	70% Ethanol.....	87
2.2.9	Preparation of reagents for competent cells.....	87
2.2.9(a)	100 mM Calcium chloride.....	87
2.2.9(b)	10 mM Magnesium chloride.....	87
2.2.9(c)	2M Magnesium chloride.....	87
2.2.9(d)	Luria Bertani (LB) Broth.....	88
2.2.9(e)	Super optimal broth (SOB).....	88
2.2.9(f)	1M Potassium chloride (KCl).....	88
2.2.9(g)	Kanamycin antibiotic stock solution (100 mg/ml).....	88
2.2.9(h)	LB Agar with Kanamycin.....	88
2.2.10	Preparation of reagents for agarose gel electrophoresis.....	89
2.2.10(a)	5X Tris-borate-EDTA (TBE) buffer.....	89
2.2.10(b)	Ethidium bromide (10 mg/ml).....	89

2.2.11	Preparation of reagents for expression of recombinant proteins.....	89
2.2.11(a)	Terrific Broth (TB).....	89
2.2.11(b)	Salt solution.....	90
2.2.11(c)	Terrific broth with salt solution.....	90
2.2.11(d)	1 M Isopropyl β -D-1-thiogalactopyranoside (IPTG).....	90
2.2.12	Preparation of reagents for SDS-PAGE.....	90
2.2.12(a)	Stacking gel buffer (pH 6.8).....	90
2.2.12(b)	Resolving gel buffer (pH 9.3).....	90
2.2.12(c)	20% Ammonium persulfate (APS).....	91
2.2.12(d)	5X Sample buffer.....	91
2.2.12(e)	10X Running buffer.....	91
2.2.12(f)	Coomassie blue stain.....	93
2.2.12(g)	Coomassie destaining solution.....	93
2.2.13	Preparation of reagents for protein fractionation using OFFGEL.....	93
2.2.13(a)	1.25X OFFGEL sample buffer (pH 4-7).....	93
2.2.13(b)	OFFGEL rehydration solution and sample preparation.....	93
2.2.13(c)	0.2% bromophenol blue.....	94
2.2.14	Preparation of reagents for Western blot.....	94
2.2.14(a)	Towbin transfer buffer (pH 8.3).....	94
2.2.14(b)	10X Tris-buffer saline (TBS).....	94

2.2.14(c)	1X Tris buffered-saline with Tween 20 (TBS-T)	94
2.2.14(d)	1X KPL blocker.....	95
2.2.14(e)	1% (v/v) Alkali casein blocking solution.....	95
2.2.14(f)	5% Skimmed milk.....	95
2.2.14(g)	SuperBlock blocking solution.....	95
2.2.14(h)	Primary antibody.....	95
2.2.14(i)	Secondary antibody.....	95
2.2.14(j)	His-Tag monoclonal antibody.....	96
2.2.14(k)	Precision Protein™ StrepTactin-HRP antibody.....	96
2.2.14(l)	Polyclonal goat anti-rabbit-HRP antibody.....	96
2.2.14(m)	Protein marker.....	96
2.2.14(n)	SuperSignal® West Pico chemiluminescent substrate.....	97
2.2.14(o)	Developer.....	97
2.2.14(p)	Fixer.....	97
2.2.14(q)	Film.....	97
2.2.15	Preparation of reagent for native purification of Histidine (His)-tagged protein.....	98
2.2.15(a)	Protease inhibitor cocktail.....	98
2.2.15(b)	10 mg/ml lysozyme stock.....	98
2.2.15(c)	DNase 1.....	98
2.2.15(d)	10 mM lysis buffer (pH 8.0).....	98

2.2.15(e)	20 mM washing buffer (pH 4.75, 5.0, 5.25 and 8.0).....	99
2.2. 15(f)	30 mM washing buffer (pH 8.0).....	99
2.2.15(g)	40 mM washing buffer (pH 8.0).....	99
2.2.15(h)	250 mM elution buffer (pH 8.0).....	99
2.2.15(i)	Nickel-nitrilotriacetic acid (Ni-NTA) resin.....	100
2.2.15(j)	1M Protein storage buffer.....	100
2.2.16	Preparation of reagents for ELISA.....	100
2.2.16(a)	Coating buffer (pH 9.6).....	100
2.2.16(b)	3% BSA (w/v) blocking solution.....	100
2.2.16(c)	ABTS substrate solution.....	100
2.2.17	Preparation of reagents for conventional PCR.....	101
2.2.17(a)	DNA preparation.....	101
2.2.17(b)	Conventional PCR master mix.....	101
2.2.18	Preparation of reagents for real-time PCR.....	101
2.2.18(a)	DNA preparation.....	101
2.2.18(b)	Real-time PCR master mix.....	101
2.2.19	Preparation of reagents for protein electro eluter.....	102
2.2.19(a)	Protein elution buffer.....	102
2.2.20	Preparation of reagents for rapid antibody lateral flow dipstick test (antibody detection).....	102
2.2.20(a)	Nitrocellulose membrane.....	102
2.2.20(b)	Absorbent pad.....	102

2.2.20(c)	Colloidal gold conjugate IgG ₄ (Au-IgG ₄).....	103
2.2.20(d)	Lateral flow dipstick test blocking solution.....	103
2.2.20(e)	Chase buffer.....	103
2.2.20(f)	Primary antibody.....	103
2.2.21	Preparation of reagents for rapid antigen lateral flow dipstick test (antigen test).....	103
2.2.21(a)	Colloidal gold conjugate to polyclonal antibodies.....	103
2.2.22	Preparation of reagents for <i>E. histolytica</i> culture medium.....	104
2.2.22(a)	Trypticase yeast extract-iron and serum medium (TYI-S-33).....	104
2.2.22(b)	Heat-inactivated bovine serum.....	104
2.2.23	Preparation of reagents for enzymatic assay.....	104
2.2.23(a)	200 mM ammonium chloride (NH ₄ Cl).....	104
2.2.23(b)	45 mM Magnesium chloride (MgCl ₂).....	105
2.2.23(c)	25 mM phosphoenol pyruvate (PEP).....	105
2.2.23(d)	25 mM adenosine monophosphate (AMP).....	105
2.2.23(e)	25 mM β-nicotinamide adenine dinucleotide (β-NADH).....	105
2.2.23(f)	2500 U/mg of lactate dehydrogenase (LDH).....	105
2.2.23(g)	100 mM sodium phosphate buffer.....	106
2.2.23(h)	1% (w/v) bovine serum albumin solution.....	106
2.2.23(i)	12.5 mM sodium pyrophosphate dibasic (PPi).....	106
2.2.23(j)	50 mM Imidazole buffer.....	106
2.2.23(k)	50 mM Acetate buffer.....	106

2.2.23(l)	50 mM Tris buffer.....	107
2.2.23(m)	50 mM Glycine-NaOH buffer.....	107
2.2.24	Preparation of reagents for <i>in vitro</i> screening of selected compound against rPPDK.....	107
2.2.24(a)	Compound stock solutions.....	107
2.2.25	Preparation of reagents for <i>in vitro</i> screening of potential compound against <i>E. histolytica</i>	107
2.2.25(a)	1X Hanks balance salt solution (HBSS).....	107
2.2.25(b)	0.05% (w/v) Nitro blue tetrazolium (NBT) solution.....	108
2.3	Methods.....	108

PART I

2.3.1	Recombinant plasmids for PPDK and Gal/GalNAc lectin.....	108
2.3.1(a)	Information of cloning sequence, vector and protein.....	108
2.3.1(b)	Preparation of <i>E. coli</i> competent cells.....	109
2.3.1(c)	Transformation of recombinant clones into expression hosts, BL21 (DE3) and <i>E. coli</i> TOP10.....	109
2.3.1(d)	Screening of positive recombinant clones.....	110
2.3.1(d)(i)	Extraction of recombinant plasmids.....	110
2.3.1(d)(ii)	Determination of plasmid concentration and purity.....	111
2.3.1(d)(iii)	Sequence analysis of the recombinant plasmid.....	111

2.3.1(d)(iv)	Preparation of glycerol stock for long term storage.....	111
2.3.2	Expression of rPPDK and rGal/GalNAc lectin proteins.....	112
2.3.2(a)	Determination of solubility of recombinant proteins.....	112
2.3.3	Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).....	113
2.3.4	Optimization of the expression of the recombinant proteins.....	113
2.3.4(a)	Optimization of post-induction temperature.....	114
2.3.4(b)	Optimization of IPTG concentration.....	114
2.3.4(c)	Optimization of period of post-induction.....	115
2.3.5	Large scale protein expression.....	115
2.3.6	Purification of the expressed recombinant proteins.....	115
2.3.6(a)	Preparation of protein sample under native condition.....	115
2.3.6(b)	Optimization of purification for rPPDK and rGal/GalNAc lectin proteins.....	116
2.3.6(b)(i)	Determination of resin to lysate volume ratio.....	116
2.3.6(b)(ii)	Determination of isoelectric point (pI) of contaminant proteins.....	117
2.3.6(b)(iii)	Purification of rPPDK and rGal/GalNAc lectin protein using washing buffers with different pH values.....	118
2.3.7	Buffer exchange of the purified recombinant proteins.....	118

2.3.8	Determination of protein concentration.....	119
2.3.9	Confirmation of the recombinant proteins by MALDI-ToF/ToF analysis.....	120
2.3.10	Western blot analysis.....	120
2.3.10(a)	Protein transfer onto nitrocellulose (NC) membrane.....	120
2.3.10(a)(i)	Determination of the presence of Histidine-tagged rPPDK and rGal/GalNAc lectin proteins.....	120
2.3.10(b)	Estimation of molecular mass of protein in Western blot.....	121
2.3.10(c)	Signal visualization by chemiluminescence substrate.....	121
2.3.10(d)	Optimizations of Western blot.....	122
2.3.10(d)(i)	Optimization of antigen amount...	122
2.3.10(d)(ii)	Optimization of primary antibody dilution.....	122
2.3.10(d)(iii)	Optimization of secondary antibody dilution.....	123
2.3.11	Evaluation of the diagnostic sensitivity and specificity of rPPDK and rGal/GalNAc lectin protein by Western blot.....	124
2.3.12	Development of lateral flow dipstick test for antibody detection.....	125
2.3.12(a)	Preparation of lateral flow dipstick test strips.....	125
2.3.12(b)	Procedure for lateral flow dipstick test.....	127

2.3.12(c)	Optimization of lateral flow dipstick test.....	127
2.3.12(c)(i)	Optimization of antigen concentrations on the test line.....	127
2.3.12(c)(ii)	Optimization of the optical density (OD) of colloidal gold conjugate.....	127
2.3.13	Evaluation of diagnostic sensitivity and specificity of lateral flow dipstick test for antibody detection.....	129
PART II		
2.3.14	Analysis of stool samples.....	130
2.3.14(a)	TechLab II <i>E. histolytica</i> ELISA.....	130
2.3.14(b)	DNA detection methods.....	131
2.3.14(b)(i)	DNA extraction from stool.....	131
2.3.14(b)(ii)	Conventional PCR.....	132
2.3.14(b)(iii)	Agarose gel electrophoresis.....	133
2.3.14(c)	Real-time PCR.....	134
2.3.14(c)(i)	Detection limit.....	134
2.3.14(c)(ii)	Assessment of real-time PCR.....	134
2.3.15	Development of lateral flow dipstick test for antigen detection.....	135
2.3.15(a)	Polyclonal antibodies production.....	135
2.3.15(a)(i)	Preparation of gel.....	135
2.3.15(a)(i)	Preparation of immunogen.....	135

2.3.15(a)(iii)	Casting and running the electro-eluter.....	135
2.3.15(a)(iv)	Eluted protein recovery.....	136
2.3.15(a)(v)	Preparation of immunogen using electroeluted protein with Freund's adjuvant.....	136
2.3.15(a)(vi)	Rabbit immunization.....	137
2.3.15(a)(vii)	Sampling of blood from rabbit-marginal ear vein.....	137
2.3.15(a)(viii)	Cardiac puncture.....	138
2.3.15(b)	Determination of antibody titer.....	139
2.3.15(b)(i)	Optimization of antigen concentration for ELISA.....	139
2.3.15(b)(ii)	Optimization of the secondary antibody dilution for ELISA.....	140
2.3.15(b)(iii)	Titration of polyclonal antibody.....	140
2.3.15(b)(iv)	Purification of polyclonal antibodies.....	141
2.3.15(b)(v)	Analysis of purified rabbit polyclonal antibodies by SDS-PAGE and Western blot.....	141
2.3.15(c)	Preparation of lateral flow dipstick strip.....	142
2.3.15(c)(i)	Procedure for lateral flow dipstick test.....	142
2.3.15(d)	Determination of the best combination of antibody test line and gold conjugated	

	antibody.....	144
2.3.15(e)	Optimization of lateral flow dipstick test.....	146
2.3.15(e)(i)	Optimization of antibody concentration on test line.....	146
2.3.15(e)(ii)	Optimization of the optical density (OD) of colloidal gold conjugate antibody.....	147
2.3.16	Detection limit of the lateral flow antigen detection dipstick...	147
2.3.17	Evaluation of the diagnostic sensitivity and specificity of lateral flow dipstick test for antigen detection.....	148
PART III		
2.3.18	Preparation of culture medium and maintenance of culture.....	149
2.3.18(a)	Axenic culture of <i>E. histolytica</i> trophozoites.....	149
2.3.18(a)(i)	Maintenance of <i>E. histolytica</i> culture.....	149
2.3.18(a)(ii)	Cell counting.....	150
2.3.19	rPPDK enzymatic assay.....	150
2.3.19(a)	Determination of optimum pH.....	151
2.3.19(b)	Determination of optimum temperature.....	151
2.3.19(c)	Kinetic data analysis.....	152
2.3.20	Information on outsourced structural-based modelling and virtual screening of potential compounds against <i>E. histolytica</i> PPDK.....	152
2.3.21	<i>In vitro</i> screening of NCI compounds as potential inhibitors	

using PPDK enzyme assay.....	153
2.3.22 <i>In vitro</i> screening of selected compounds against trophozoites of <i>E. histolytica</i> by minimum inhibitory concentration (MIC) assay.....	154
2.3.23 <i>In vitro</i> cell viability by NBT reduction assay to determine IC ₅₀ value.....	158
2.3.24 Determination of mortality rate at IC ₅₀ value.....	160

CHAPTER THREE: RESULTS

PART I

3.1 Confirmation of PPDK and Gal/GalNAc lectin clones by DNA sequencing and alignment	163
3.2 Recombinant protein expression.....	166
3.2.1 Determination of protein solubility.....	166
3.3 Optimization of the expression of the rPPDK and rGal/GalNAc lectin proteins.....	166
3.3.1 Optimization of post-induction temperature.....	166
3.3.2 Optimization of IPTG concentration.....	170
3.3.3 Optimization of the period post-induction.....	170
3.4 Detection of Histidine-tagged rPPDK and rGal/GalNAc lectin proteins.....	175
3.5 Analysis of rPPDK and rGal/GalNAc lectin protein bands by MALDI- ToF/ToF.....	175
3.6 Purification of rPPDK and rGal/GalNAc lectin.....	183
3.6.1 Optimization of the ratio of resin to lysate volume for rPPDK purification.....	183
3.6.2 Optimization of washing buffers at various pH for purification of rPPDK.....	188

3.6.3	Optimization of resin to lysate volume ratio for rGal/GalNAc lectin purification.....	197
3.6.4	Optimization of pH of washing buffer for purification of rGal/GalNAc lectin.....	200
3.7	Optimizations of various parameters of Western blot	206
3.7.1	Optimization of antigen amount.....	206
3.7.2	Optimization of primary antibody dilution.....	211
3.7.3	Optimization of secondary antibody dilution.....	214
3.8	Evaluation of diagnostic sensitivity and specificity of rPPDK and rGal/GalNAc lectin proteins.....	220
3.9	Development of lateral flow dipstick test for antibody detection.....	224
3.9.1	Optimization of recombinant protein concentration on test line.....	224
3.9.2	Optimization of OD values of gold conjugated IgG4.....	227
3.10	Evaluation of diagnostic sensitivity and specificity of lateral flow dipstick test (antibody detection)	229
 PART II		
3.11	Analysis of stool samples.....	232
3.11.1	Conventional PCR for detection of <i>E. histolytica</i> , <i>E. dispar</i> , and <i>E. moshkovskii</i>	232
3.11.2	Real-time PCR for detection of <i>E. histolytica</i> and <i>E. dispar</i>	237
3.11.3	Antigen detection test using TechLab <i>E. histolytica</i> II ELISA.....	241
3.12	Development of lateral flow dipstick for antigen detection test.....	243
3.12.1	Production of polyclonal antibodies.....	243

3.12.1(a)	Optimization of antigen concentration and secondary antibody in ELISA for production of polyclonal antibodies.....	243
3.12.1(b)	Determination of polyclonal antibody titer	247
3.12.1(c)	Purification of polyclonal antibodies and Western blot analysis.....	250
3.12.2	Evaluation of various combinations of antibodies and conjugates pairs in the lateral flow dipstick test.....	253
3.12.3	Optimization of polyclonal antibody concentration on test line.....	257
3.12.4	Optimization of OD of gold conjugated antibody.....	261
3.12.5	Determination of detection limit of the antigen test strip.....	261
3.13	Evaluation of diagnostic sensitivity and specificity of the lateral flow antigen detection dipstick test	268

PART III

3.14	Optimization of rPPDK enzyme assay.....	274
3.14.1	Optimization of pH.....	274
3.14.2	Optimization of temperature.....	274
3.15	Kinetic characterization of rPPDK.....	276
3.16	<i>In vitro</i> screening of selected PPDK inhibitors using rPPDK enzyme assay.....	280
3.17	<i>In vitro</i> susceptibility testing of <i>E. histolytica</i>	282
3.18	Anti-amoebic activity of selected compound against <i>E. histolytica</i>	284

CHAPTER FOUR: DISCUSSION

Part I	Development of a rapid antibody test for diagnosis of extraintestinal amoebiasis.....	290
Part II	Development of a rapid antibody test for diagnosis of extraintestinal amoebiasis.....	300
Part III	Identification of potential anti-amoebic agents against <i>E. histolytica</i>	312
CHAPTER FIVE: CONCLUSIONS AND RECOMMENDATIONS		323
Limitations of the study and suggestions for further studies.....		327
REFERENCES.....		329
APPENDICES.....		368

LIST OF TABLES

	Page
Table 1.1	Characteristics of trophozoites and cysts of common intestinal <i>Entamoeba</i> species 32-33
Table 1.2	Commercially antigen detection assays for diagnosis of intestinal amoebiasis 37-38
Table 1.3	The sensitivity and specificity of commercially available antibody detection assays for diagnosis of amoebiasis 51
Table 1.4	Drugs treatment, mechanism and adverse effect of drugs for treatment of amoebiasis 58
Table 2.1	Primers used for detection of <i>E. histolytica</i> , <i>E. dispar</i> and <i>E. moshkovskii</i> species by conventional PCR 81
Table 2.2	Primers and probes sequence used for detection of <i>E. histolytica</i> and <i>E. dispar</i> by real-time PCR 81
Table 2.3	Chemical properties of selected compounds from outsourced <i>in-silico</i> modelling and virtual screening of <i>E. histolytica</i> pyruvate phosphate dikinase 83
Table 2.4	Recipes for preparing 10% SDS-PAGE gel..... 92
Table 2.5	Screening for potential combination of antibody test line and gold conjugated antibody..... 145
Table 2.6	Scoring of trophozoites growth 157
Table 3.1	Summary of the result of identification of <i>E. histolytica</i> proteins at 98 kDa and 53 kDa protein bands using mass-spectrometry..... 177
Table 3.2	The pH values from the OFFGEL fractions 189 & 202

Table 3.3	Optimization of pH in phosphate buffers containing 20 mM imidazole used for purification of rPPDK protein	190
Table 3.4	Optimization of pH in phosphate buffers containing 20 mM imidazole used for purification of rGal/GalNAc lectin protein	201
Table 3.5	Optimized parameters of Western blot for rPPDK and rGal/GalNAc lectin proteins	219
Table 3.6	Summary of Western blots reactivities of the rPPDK and rGal/GalNAc lectin probed with anti-human IgG-HRP, IgG ₁ -HRP and IgG ₄ -HRP	223
Table 3.7	Diagnostic sensitivity and specificity of the lateral flow dipstick for detection of anti-PPDK antibodies in serum samples	230
Table 3.8	Summary of PCR results for <i>E. histolytica</i> , <i>E. dispar</i> and <i>E. moshkovskii</i> among 45 microscopy-positive stool samples.....	233
Table 3.9	Results of the detection limit by using a pTEh plasmid	238
Table 3.10	Results of the detection limit by using a pTEd plasmid	238
Table 3.11	Results of the 45 microscopy-positive stool samples for <i>Entamoeba</i> species using real-time PCR	240
Table 3.12	Details of <i>Entamoeba</i> species detected by real-time PCR.....	240
Table 3.13	Result of microscopy and TechLab <i>E. histolytica</i> II ELISA for detection of <i>E. histolytica</i> infection in stool samples (n=70).....	242
Table 3.14(a)	Optimization of rPPDK concentration for coating ELISA microplate	244

Table 3.14(b)	Optimization of rGal/GalNAc lectin concentration for coating ELISA microplate	244
Table 3.14(c)	Optimization of Eh-ESA concentration for coating ELISA microplate	245
Table 3.15(a)	Optimization of the dilution of goat anti-rabbit HRP as secondary antibody (anti-rPPDK IgG) in ELISA.....	245
Table 3.15(b)	Optimization of the dilution of goat anti-rabbit HRP as secondary antibody (anti-rGal/GalNAc lectin IgG) in ELISA.....	246
Table 3.15(c)	Optimization of the dilution of goat anti-rabbit HRP as secondary antibody (anti-Eh ESA IgG) in ELISA	246
Table 3.16	Screening for potential combination of test line and gold conjugated polyclonal antibody	254
Table 3.17	Combination of antibody on test line and gold conjugated antibody that did not give non-specific binding on the dipstick without the antigens (rPPDK, rGal/GalNAc lectin or Eh-ESA).....	255
Table 3.18	Evaluation of detection of the dipstick test with different combinations of test lines and conjugated polyclonal antibodies.....	256
Table 3.19	Summary of optimization of polyclonal antibody (anti-rPPDK) concentrations on test line.....	260
Table 3.20	Summary of optimization of OD of conjugated anti-ESA antibody.....	264
Table 3.21	Diagnostic sensitivity of the dipstick test as compared to real-time PCR using 45 microscopy-positive stool sample...	270
Table 3.22	Diagnostic sensitivity of the dipstick test in detecting <i>E. histolytica</i> among single and mixed infection.....	270

Table 3.23	Diagnostic sensitivity of the dipstick test compared to TechLab <i>E. histolytica</i> II ELISA	270
Table 3.24	Optimization of polyclonal antibody (anti-rGal/GalNAc lectin) concentrations on test line	272
Table 3.25	Optimization of OD of conjugated polyclonal antibody (anti-rGal/GalNAc lectin).....	272
Table 3.26	Diagnostic sensitivity of the dipstick test compared to real-time PCR (anti/rGal-Gal/NAc lectin combination pair).....	272
Table 3.27	Diagnostic specificity of the dipstick test (anti-rPPDK/anti-Eh ESA combination pair).....	273
Table 3.28	Diagnostic specificity of the dipstick test (anti/rGal-Gal/NAc lectin combination pair).....	273
Table 3.29	Comparison of K_m for three substrates of PPDK from different sources	279
Table 3.30	Inhibition constants value (K_i) of various compounds against rPPDK	281
Table 3.31	Summary of MIC assay scores of ten NCI compounds and metronidazole after 24 and 48 hours of treatment.....	283
Table 3.32	The effect of compounds and metronidazole at IC_{50} on the <i>in vitro</i> growth of <i>E. histolytica</i> trophozoites at different incubation periods	287

LIST OF FIGURES

	Page
Figure 1.1	Morphological descriptions of <i>E. histolytica</i> / <i>E. dispar</i> trophozoites and cyst 5
Figure 1.2	Life cycle of <i>E. histolytica</i> 8
Figure 1.3	Microscopic observations of invasive intestinal amoebiasis..... 19
Figure 1.4	Amoebic liver abscess..... 22
Figure 1.5	The amoebas found in stool specimens of humans 31
Figure 1.6	The PP _i -dependent extended glycolytic pathway of <i>E. histolytica</i> 63
Figure 2.1(a)	(Part I) Evaluations of immunoreactivity of the purified recombinant proteins, development and evaluation of a lateral flow dipstick test for antibody detection 73
Figure 2.1(b)	(Part II) Development and evaluation of a lateral flow dipstick test for stool antigen detection..... 74
Figure 2.1(c)	(Part III) <i>In-vitro</i> screening of PPK inhibitors for discovery of potential anti-amoebic compounds 75
Figure 2.2	Two-dimensional chemical structures of molecules selected as potential anti-amoebic agents..... 84-85
Figure 2.3	Schematic diagram of lateral flow dipstick test for antibody detection. 126
Figure 2.4	Schematic diagrams showing lateral flow dipstick test procedure for antibody detection 128
Figure 2.5	Schematic diagrams showing lateral flow dipstick test procedure for antigen detection test 143

Figure 2.6	The layout of <i>in vitro</i> MIC assay in a 96-well plate	155
Figure 2.7	The layout of NBT reduction assay in a 96-well plate...	159
Figure 2.8	The layout of assay to determine the mortality rate at IC ₅₀ value in a 96-well plate.....	161
Figure 3.1	Map of pET28a expression vector showing the location of PPDK gene embedded in the vector sequence	164
Figure 3.2	Map of pET28a expression vector showing the location of Gal/GalNAc lectin gene embedded in the vector sequence.....	165
Figure 3.3	SDS-PAGE analysis of the expressed rPPDK and rGal/GalNAc lectin protein in supernatant (soluble fraction) and pellet (insoluble fraction)	167
Figure 3.4(a)	SDS-PAGE showing induction of rPPDK with 1 mM IPTG for 4 hours at different incubation temperatures...	168
Figure 3.4(b)	SDS-PAGE showing induction of rGal/GalNAc lectin expression with 1 mM IPTG for 4 hours with different incubation temperatures	169
Figure 3.5(a)	SDS-PAGE showing induction of rPPDK at 30°C for 4 hours with various IPTG concentrations	171
Figure 3.5(b)	SDS-PAGE showing induction of rGal/GalNAc lectin at 30°C for 4 hours with various IPTG concentrations ..	172
Figure 3.6(a)	Induction of rPPDK with 1 mM IPTG at various durations of incubation period post-induction	173
Figure 3.6(b)	SDS-PAGE showing induction of rGal/GalNAc lectin with 1 mM IPTG at various durations of incubation period post-induction	174
Figure 3.7(a-b)	Western blot analysis of rPPDK and rGal/GalNAc lectin proteins incubated with mouse monoclonal anti-	

	histidine-HRP	176
Figure 3.8(a)	Protein summary report for rPPDK protein	179
Figure 3.8(b)	Peptide summary report for rPPDK protein.....	180
Figure 3.9(a)	Protein summary report for rGal/GalNAc lectin protein.....	181
Figure 3.9(b)	Peptide summary report for rGal/GalNAc lectin protein.....	182
Figure 3.10	SDS-PAGE of Ni-NTA purification of rPPDK protein.....	184
Figure 3.11	SDS-PAGE of Ni-NTA purification of rGal/GalNAc lectin protein.....	185
Figure 3.12(a)	SDS-PAGE analysis for rPPDK protein purification using 1:10 ratio of resin to lysate	186
Figure 3.12(b)	SDS-PAGE analysis for rPPDK protein purification using 1:20 ratio of resin to lysate	187
Figure 3.13	SDS-PAGE of OFFGEL fractions of rPPDK protein using OFFGEL High Res Kit, pH 4-7.....	189
Figure 3.14(a)	SDS-PAGE of rPPDK purification using 20 mM washing buffer at pH 4.75.....	191
Figure 3.14(b)	SDS-PAGE of rPPDK purification using 20 mM washing buffer at pH 5.0.....	192
Figure 3.14(c)	SDS-PAGE of rPPDK purification using 20 mM washing buffer at pH 5.25.....	194
Figure 3.14(d)	SDS-PAGE of rPPDK purification using 20 mM washing buffer at pH 4.75 and 5.0.....	195
Figure 3.14(e)	SDS-PAGE of rPPDK purification using 20 mM	

	washing buffer at pH 5.0 and 5.25.....	196
Figure 3.15(a)	SDS-PAGE analysis for rGal/GalNAc lectin protein purification using 1:10 ratio of resin to lysate	198
Figure 3.15(b)	SDS-PAGE analysis for rGal/GalNAc lectin protein purification using 1:20 ratio of resin to lysate	199
Figure 3.16	SDS-PAGE of OFFGEL fractions of rGal/GalNAc lectin protein using OFFGEL High Res Kit, pH 4-7.....	202
Figure 3.17(a)	SDS-PAGE of rGal/GalNAc lectin purification using 20 mM washing buffer at pH 4.75.....	203
Figure 3.17(b)	SDS-PAGE of rGal/GalNAc lectin purification using 20 mM washing buffer at pH 5.0.....	204
Figure 3.17(c)	SDS-PAGE of rGal/GalNAc lectin purification using 20 mM washing buffer at pH 5.25.....	205
Figure 3.18(a-b)	Western blot conditions of rPPDK using different amounts of antigens probed with (a) IgG-HRP, and (b) IgG1-HRP	207
Figure 3.18(c)	Western blot conditions of rPPDK using different amounts of antigens probed with IgG4-HRP	208
Figure 3.19(a-b)	Western blot conditions of rGal/GalNAc lectin using different amounts of antigens probed with (a) IgG-HRP, and (b) IgG1-HRP	209
Figure 3.19(c)	Western blot conditions of rGal/GalNAc lectin using different amounts of antigens probed with IgG4-HRP...	210
Figure 3.20	Optimization of Western blot conditions for rPPDK with different primary antibody (serum) dilutions when probed with IgG-HRP, IgG1-HRP, and IgG4-HRP.....	212
Figure 3.21(a-b)	Optimization of Western blot conditions for rGal/GalNAc lectin with different primary antibody	

	(serum) dilutions when probed with IgG-HRP, IgG1-HRP and IgG4-HRP	213
Figure 3.22(a-b)	Optimization of Western blot conditions for rPPDK probed with different secondary antibodies dilutions, (a) rPPDK was probed with IgG-HRP and (b) rPPDK was probed with IgG1-HRP	215
Figure 3.22(c)	Optimization of Western blot conditions for rPPDK probed with IgG4-HRP	216
Figure 3.23(a-b)	Optimization of Western blot conditions for rGal/GalNAc lectin with different secondary antibody dilutions, (a) rGal/GalNAc lectin was probed with IgG-HRP, (b) rGal/GalNAc lectin was probed with IgG1-HRP.....	217
Figure 3.23(c)	Optimization of Western blot conditions for rGal/GalNAc lectin when probed with IgG4-HRP	218
Figure 3.24	Representative IgG, IgG ₁ , and IgG ₄ blots of rPPDK probed with human serum samples	221
Figure 3.25	Representative IgG, IgG ₁ and IgG ₄ blots of rGal/GalNAc lectin probed with human serum samples.....	222
Figure 3.26(a)	Rapid dipsticks using of rPPDK at concentrations ranging from 0.8 mg/ml to 1.5 mg/ml	225
Figure 3.26(b)	Rapid dipsticks using of rPPDK at concentrations ranging from 2.0 mg/ml to 2.5 mg/ml	226
Figure 3.27	Rapid dipsticks using of rPPDK at various OD ranging from OD ₄ to OD ₁₀	228
Figure 3.28	Representative images of the lateral flow dipstick test tested with various groups' serum samples	231

Figure 3.29(a)	Representative image of PCR amplification for detection of <i>E. histolytica</i> using EntaF and EhR primers.....	234
Figure 3.29(b)	Representative image of PCR amplification for detection of <i>E. dispar</i> using EntaF and EdR primers	235
Figure 3.29(c)	Representative image of PCR amplification for detection of <i>E. moshkovskii</i> using EntaF and EmR primers	236
Figure 3.30	Standard curve constructed using pTEh plasmid	239
Figure 3.31	Standard curve constructed using pTEd plasmid	239
Figure 3.32(a)	Kinetic of rabbit anti-rPPDK IgG antibody at different time intervals	248
Figure 3.32(b)	Kinetic of rabbit anti-rGal/GalNAc lectin IgG antibody at different time intervals.....	248
Figure 3.32(c)	Kinetic of rabbit anti-Eh ESA IgG antibody at different time intervals	249
Figure 3.33	Purification of IgG from rabbit anti-rPPDK, anti-Eh ESA, and anti-rGal/GalNAc lectin	251
Figure 3.34	Western blot analysis using anti-rPPDK, anti-rGal/GalNAc lectin, and anti-Eh ESA IgGs to detect rPPDK, rGal/GalNAc lectin, and Eh ESA	252
Figure 3.35	Representative image of screening of antibody pairs to identify those that did not give non-specific binding	255
Figure 3.36(a-b)	Representative images of the optimization of polyclonal antibody concentrations on test line at (a) 1.0 mg/ml (b) 1.5 mg/ml.....	258
Figure 3.36(c-d)	Representative images of the optimization of	

	polyclonal antibody concentrations on test line at from (c) 2.0 mg/ml (d) 2.5 mg/ml.....	259
Figure 3.37(a-b)	Representative images for the optimization of OD of gold conjugated anti-Eh ESA IgG using dipstick strips at 2.0 mg/ml (OD4 and OD6).....	262
Figure 3.37(c)	Representative images for the optimization of OD of gold conjugated anti-Eh ESA IgG using dipstick strips at 2.0 mg/ml (OD8).....	263
Figure 3.38	Analytical sensitivity of dipstick test strips to detect rPPDK spiked in PBS at various concentrations	265
Figure 3.39	Analytical sensitivity of dipstick test strips to detect rPPDK spiked in a negative stool sample at various concentrations.....	266
Figure 3.40	Analytical sensitivity of dipstick test strips to detect antigen from lysed <i>E. histolytica</i> trophozoites that had been spiked in a negative stool sample at various concentrations.....	267
Figure 3.41	Representative image of dipstick test using a positive and negative stool samples	269
Figure 3.42	Determination of optimum pH for rPPDK	275
Figure 3.43	Determination of optimum temperature for rPPDK using imidazole-HCl buffer at pH 6.3.....	275
Figure 3.44	Determination of rPPDK Michaelis-Menten kinetic constants for PPi substrate	277
Figure 3.45	Determination of rPPDK Michaelis-Menten kinetic constants for PEP substrate	277
Figure 3.46	Determination of rPPDK Michaelis-Menten kinetic constants for AMP substrate	278

Figure 3.47(a)	<i>In vitro</i> effect of NSC349156, NSC228137 and metronidazole against <i>E. histolytica</i> trophozoites after 24 hours.....	286
Figure 3.47(b)	<i>In vitro</i> effect of NSC349156, NSC228137 and metronidazole against <i>E. histolytica</i> trophozoites after 48 hours	286
Figure 3.47(b)	<i>In vitro</i> effect of NSC349156, NSC228137 and metronidazole against <i>E. histolytica</i> trophozoites after 48 hours	286
Figure 3.48(a-c)	Microscopic examination of <i>E. histolytica</i> trophozoites at 24 hours (untreated cells, treated cells with 0.5% DMSO, treated cells with metronidazole.....	288
Figure 3.48(d-e)	Microscopic examination of <i>E. histolytica</i> trophozoites at 24 hours (treated cells with NSC349156 and NSC228137).....	289

LIST OF ABBREVIATIONS

±	more or less
°C	degree Celcius
µg	microgram
µL	microliter
µM	micromolar
ABTS	2,2'-Azino-d-[3-ethylbentiazoline sulfonate]
ALA	amoebic liver abscess
AMP	adenosine monophosphate
Anti-ESA	antibody to ESA
Anti-rGal/GalNac lectin	antibody to rGal/GalNac lectin
Anti-rPPDK	antibody to rPPDK
APS	ammonium persulfate
APS	ammonium persulfate
Au-IgG4	colloidal gold conjugate IgG4
bp	base pair
BSA	bovine serum albumin
CDC	Centre for Disease Control
CHO	chinese hamster ovary
CIE	counterimmunoelectrophoresis
CRD	carbohydrate-recognition domain
CS1	cysteine synthase 1
CS3	cysteine synthase 3
CT	computed tomography
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
dNTPs	deoxynucleoside triphosphates
<i>E. coli</i>	<i>Escherichia coli</i>
e.g.	<i>Exempli gratia</i> -‘for example’
ECL	enhanced chemiluminescent
Eh	<i>Entamoeba histolytica</i>
EhHK1	<i>E. histolytica</i> hexokinase 1
ELISA	enzyme linked immunosorbent assay

ESA	Excretory-secretory antigen
<i>et al</i>	<i>Et alii</i> - ‘and others’
FDA	Food and Drug Administration
FECT	Formalin-ether concentration technique
<i>g</i>	gravity
<i>g</i>	gram
Gal/GalNAc	galactose and N-acetyl-D-galactosamine
HBA	hydrogen binding acceptor
HBD	hydrogen binding donor
HE	hematoxylin and eosin stain
His	histidine
Hgl	heavy subunit of by galactose-inhibitable lectin protein
HL Y6	haemolysin gene
HRP	horseradish peroxidase
HTS	high-throughput screening
HUSM	Hospital Universiti Sains Malaysia
IC ₅₀	concentration of an inhibitor where the response (or binding) is reduced by half
IEC	intestinal epithelial cells
IFA	immunoflouresence assay
IFA	indirect immunofluorescence assay
IFN- γ	interferon gamma
Ig	immunoglobulin
Igl1	intermediate subunit of by galactose-inhibitable lectin protein
IHA	indirect haemagglutination assay
IHA	indirect haemagglutination
INFORMM	Institute for Research in Molecular Medicine
IPG	immobilized pH gradient
IPTG	isopropyl β -D-1-thiogalactopyranoside
kDa	kilodalton
<i>K_i</i>	inhibition constant
<i>km</i>	Michaelis-Menten constant

kVh	kilovolt per hour
LAMP	loop-mediated isothermal amplification assay
LB	Luria bertani
LDH	lactate dehydrogenase
mAB	monoclonal antibody
Lgl	light subunit of by galactose-inhibitable lectin protein
MALDI-TOF/TOF	matrix-laser desorption/ionization-time of flight/ time of flight
mg	Milligram
MIC	minimal inhibitory concentration
mM	Milimolar
MPPP	Penang City Council
NAD	oxidized nicotinamide adenine dinucleotide
NBT	nitro-blue tetrazolium
NC	nitrocellulose membrane
NCI	National Cancer Institute
NF- κ B	nuclear factor kappa
Ni-NTA	nickel-nitrilotriacetic acid
nm	Nanometers
NO	nitric oxide
NTC	non-template control
NTD	neglected tropical diseases
OASS	O-acetyl-L-serine sulfhydrylase
OD	optical density
ORF	open reading frame
PAS	periodic acid–Schiff
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PEP	Phosphoenolpyruvate
PFK	phosphofructo-1-kinase
PFOR	pyruvate ferredoxin oxidoreductase
pI	isoelectric point
Pi	inorganic phosphate

pI	isoelectric point
PLA	pyogenic liver abscess
POC	point-of-care
PPDK	pyruvate phosphate dikinase
PPi	pyrophosphate dibasic
PST-1	pancratistatin
PVA	polyvynil alcohol
Pyr	pyruvate
RBC	red blood cells
RC DC™	reducing agent detergent compatible
rDNA	ribosomal DNA
rGal/GalNAc lectin	recombinant galactose and N-acetyl-D-galactosamine lectin
rpm	rotation per minute
rPPDK	recombinant pyruvate phosphate dikinase
SAP	soluble amoebic proteins
Sat-ase	serine acetyltransferase
SDS-PAGE	sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SOB	super optimal broth
SREHP	serine-rich <i>E. histolytica</i>
TB	terrific broth
TBE	tris-borate-EDTA
TBS	tris buffer saline
TCA	tricarboxylic acid
TEMED	tetramethylethylenediamine
TLR	toll-like receptor
TIM	triosephosphate isomerase
TPP	Triage Parasite Panel
U	enzyme unit
UV	ultra violet
<i>V_{max}</i>	maximum rate
WHO	World Health Organization
β-NADH	nicotinamide adenine dinucleotide

**REKOMBINAN PIRUVAT FOSFAT DIKINASE (rPPDK): PEMBANGUNAN
UJIAN DIPSTIK PANTAS ANTIBODI DAN ANTIGEN BAGI AMEBIASIS
DAN PENGENALPASTIAN POTENSI SEBATIAN ANTI-AMEBIK**

ABSTRAK

Amebiasis, sejenis penyakit protozoa enterik yang disebabkan oleh *Entamoeba histolytica*, merupakan satu masalah kesihatan awam di kebanyakan negara membangun. Amebiasis intestinal boleh menyebabkan simptom seperti kolitis dan disenteri; manakala amebiasis ekstraintestinal kebiasaannya menyebabkan abses hepar jangkitan ameba (ALA). Asai pengesanan antigen komersil yang tersedia untuk jangkitan intestinal menunjukkan sensitiviti dan spesifisiti yang berbeza-beza manakala ujian yang tersedia untuk ALA menggunakan ekstrak asli antigen parasit mempunyai isu spesifisiti. Sebelum ini, piruvat fosfat dikinase (PPDK) telah dikenalpasti sebagai penanda untuk mengesan amebiasis ekstraintestinal, maka protein dalam bentuk rekombinan (rPPDK) digunakan dalam kajian ini untuk membangunkan ujian pantas dipstik antibodi untuk ALA. Pencarian ejen anti-amebik sangat penting kerana kesan sampingan metronidazole dan laporan kerintangan terhadapnya. PPDK terlibat dalam laluan utama metabolisme tenaga parasit, maka PPDK merupakan satu sasaran yang berpotensi untuk pembangunan ejen anti-amebik baharu. Oleh itu, kajian ini juga bertujuan untuk menyiasat aktiviti anti-amebik secara in vitro daripada sebatian berpotensi dengan menggunakan *E. histolytica* HM-1: IMSS. Gen PPDK telah ditempah untuk diklonkan ke dalam vektor pengekspresan pET28, ditransformasikan ke dalam *E. coli* BL21 (DE3), diekspreskan dan dituliskan. Sensitiviti dan spesifisiti diagnostik bagi protein tulen rPPDK dinilai melalui pembloatan Western dengan menggunakan sampel serum individu. Untuk perbandingan, prosedur di atas juga dijalankan untuk menghasilkan rekombinan

galaktosa-dan-N-asetil-D-galaktosamina lektin boleh rencat (rGal/GalNAc lektin). Ujian pembloatan Western menggunakan serum daripada pesakit ALA, individu yang sihat dan penyakit lain yang ditanda dengan menggunakan anti-manusia IgG4-berkonjugat horseradish menunjukkan nilai sensitiviti (93.3%) dan spesifisiti (100%) diagnostik paling tinggi berbanding blot yang menggunakan IgG dan IgG1 sebagai antibodi kedua. rPPDK menunjukkan spesifisiti yang lebih baik jika dibandingkan dengan rGal/GalNAc lektin. Ujian pantas dipstik aliran sisi dengan menggunakan rPPDK telah dibangunkan dan dinilai untuk serodiagnosis ALA menggunakan sampel serum daripada pesakit dan kawalan. Keputusan menunjukkan sensitiviti diagnostik sebanyak 96.7% (n=29/30) dan spesifisiti 100% (n=40/40). Dalam membangunkan ujian pantas pengesanan antigen untuk amebiasis intestinal, antibodi poliklonal (PAb) kepada rPPDK, rGal/GalNAc lektin dan antigen perkumuhan-rembesan *E. histolytica* (Eh ESA) telah dihasilkan. Pengesanan terbaik *E. histolytica* dalam sampel tinja ditunjukkan apabila anti-rPPDK PAb digariskan pada dipstik dan PAb anti-Eh ESA berkonjugat-emas digunakan sebagai reagen pengesanan. Prestasi ujian dipstik aliran sisi yang dibangunkan telah dibandingkan dengan ujian komersial TechLab *E. histolytica* II ELISA dan ujian PCR “real-time”, menggunakan 70 sampel tinja daripada pesakit dan kawalan. Sepuluh sebatian daripada Institut Kanser Kebangsaan (NCI) telah dipilih daripada saringan maya sebelum ini yang dilakukan ke atas tapak ATP model tiga dimensi PPDK. Dengan menggunakan asai enzim, tujuh sebatian menunjukkan aktiviti rencatan, merangkumi NSC349156 dan NSC228137 yang menunjukkan nilai MIC masing-masing pada 25 μM dan 50 μM . Dengan menggunakan asai penurunan NBT, NSC349156 menunjukkan nilai IC_{50} yang terendah (14.04 μM), diikuti oleh NSC228137 (20.7 μM); manakala IC_{50} bagi metronidazole ditentukan pada nilai 6.15 μM . Selepas 24 jam rawatan, NSC228137

dan NSC349156 masing-masing menunjukkan 37.61% dan 75.73% rencatan pertumbuhan. Kesimpulannya, rPDDK telah berjaya digunakan dalam pembangunan ujian pantas antibodi dan juga ujian pengesan antigen masing-masing untuk diagnosis ekstraintestinal dan intrainestinal amebiasis. Tambahan pula, dua sebatian menunjukkan potensi untuk bertindak sebagai agen anti-amebik.

**RECOMBINANT PYRUVATE PHOSPHATE DIKINASE (rPPDK):
DEVELOPMENT OF ANTIBODY AND ANTIGEN RAPID DIPSTICK
TESTS FOR AMOEBIASIS AND IDENTIFICATION OF POTENTIAL ANTI-
AMOEBIC COMPOUNDS**

ABSTRACT

Amoebiasis, an enteric protozoan disease caused by *Entamoeba histolytica*, is a public health problem in many developing countries. Intestinal amoebiasis may produce symptoms such as colitis and dysentery; while extraintestinal amoebiasis commonly results in amoebic liver abscess (ALA). The commercial antigen detection tests for intestinal infection vary in their sensitivities and specificities; most of them use native parasite antigen extract which have specificity issues. Thus this study was aimed at improving the laboratory diagnosis of ALA and intestinal amoebiasis. Previously, pyruvate phosphate dikinase (PPDK) had been identified as a marker for detection of extraintestinal amoebiasis, thus the recombinant form of the protein (rPPDK) was used in this study to develop a rapid antibody dipstick test for ALA. Search for new anti-amoebic agents is important due to the side-effects of metronidazole and reports of resistance against it. PPDK is involved in a key pathway in the energy metabolism of the parasite, thus is a promising target for a new anti-amoebic agent. Therefore, the present study was also aimed to investigate *in vitro* anti-amoebic activity of potential compounds using *E. histolytica* HM-1: IMSS. The PPDK gene was custom cloned into pET28a(+) expression vector, transformed into *E. coli* BL21 (DE3), expressed and purified. Diagnostic sensitivity and specificity of the purified rPPDK protein were evaluated by Western blot using individual serum samples. For comparison, the above procedures were also performed to produce recombinant galactose-and-N-acetyl-D-galactosamine

inhibitable lectin (rGal/GalNAc lectin). Western blots using patients and control serum samples probed with anti-human IgG4-HRP showed higher diagnostic sensitivity (93.3%) and specificity (100%) as compared to blots using IgG and IgG1 as secondary antibodies. rPPDK was found to show better specificity when compared to rGal/GalNAc lectin. A rapid dipstick test using rPPDK was developed and evaluated for ALA serodiagnosis. The results showed 96.7% (n=29/30) diagnostic sensitivity and 100% (n=40/40) specificity. For the development of an antigen detection rapid test for intestinal amoebiasis, polyclonal antibody (PAb) against rPPDK, rGal/GalNAc lectin and *E. histolytica* excretory-secretory antigens (Eh ESA) were produced. The best detection of *E. histolytica* in stool samples was shown when anti-rPPDK PAb was lined on the dipstick and gold conjugated anti-Eh ESA PAb was used as the detector reagent. Performance of the developed dipstick test was compared with commercial TechLab *E. histolytica* II ELISA and real-time PCR, using 70 stool samples from patients and controls. Ten compounds from the National Cancer Institute (NCI) were selected from a previous virtual screening performed against ATP site of a three-dimensional PPDK model. Using an enzymatic assay, seven of the compounds showed inhibitory activities, they include NSC349156 and NSC228137 with MIC values of 25 μ M and 50 μ M respectively. Using NBT reduction assay, NSC349156 showed the lowest IC₅₀ (14.04 μ M), followed by NSC228137 (20.7 μ M); while IC₅₀ of metronidazole was 6.15 μ M. After 24 hours of treatment, NSC228137 and NSC349156 exhibited 37.61% and 75.73% growth inhibition, respectively. In conclusion, rPPDK was successfully used in this study for development of rapid antibody and antigen detection tests for diagnosis of extraintestinal and intestinal amoebiasis respectively. In addition, two compounds showed potential to serve as anti-amoebic agents.

CHAPTER ONE

INTRODUCTION

1.1 Overview of amoebiasis

Neglected tropical diseases (NTD) are a diverse group of chronic and disabling diseases that are found in very poor areas and affect more than one billion people globally (Hotez *et al.*, 2007). Many of the world's NTDs occur in poor populations in twenty countries (Group of 20), which are mostly tropical and subtropical such as Brazil, Mexico, Indonesia, India, Bangladesh and China (Hotez *et al.*, 2013). The major parasitic diseases of the NTDs include amoebiasis, malaria, leishmaniasis, Chagas's disease, schistosomiasis, lymphatic filariasis, strongyloidiasis, ascariasis, onchocerciasis and trichuriasis. Amoebiasis (caused by *Entamoeba histolytica*) is estimated to affect 50 million people worldwide and causes up to 100 000 deaths annually. In terms of mortality due to protozoan parasites, it ranks in second place after malaria (Stanley, 2003; Fotedar *et al.*, 2007a). Of these, 90% are asymptomatic carrier, whereas the other 10% of infected individuals show clinical symptoms such as colitis, dysentery and extraintestinal amoebiasis (Fotedar *et al.*, 2007a). The most common clinical manifestation of extraintestinal is amoebic liver abscess (ALA) and a delay in diagnosis and treatment may cause fatality (Zlobl, 2001). The disease is usually found in areas with poor sanitary conditions and low socioeconomic status. The only reservoir is humans, and infection occurs *via* food, water or hands contaminated with cyst-containing faeces. Human to human transmission has also been reported, that is, through oral-genital or oral-anal contact, especially among homosexual men (Hung *et al.*, 2008), as well as travellers from endemic areas, and those with poor personal hygiene (Rivero *et al.*, 2008).

The epidemiology of amoebiasis varies between countries and continents due to ecological, social-culture and economic factors (Blessmann *et al.*, 2002a; Haghghi *et al.*, 2003; Ali *et al.*, 2008; Ximanez *et al.*, 2009). For example, Fotedar *et al.*, (2007a) reported the prevalence of *Entamoeba* infection is as high as 50% in endemic areas of Central and South America, Africa and Asia. Hung *et al.* (2008) and Watanabe *et al.* (2011) reported an increasing risk of amoebiasis in Taiwan, Japan and South Korea, especially among homosexual men who practice oral-anal sex. In Southeast Asia, this disease is commonly found in the following communities-aborigines, those living in poor sanitary conditions, rural and urban populations with low socioeconomic status, and immigrants from amoebiasis endemic areas (Mahmud *et al.*, 2013).

Many diagnostic tests have been developed for the accurate detection of *E. histolytica* in clinical samples, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) (Packers, 2002). However, some ELISAs do not show good sensitivity and specificity when used in low to medium endemic areas, especially in developing and underdeveloped countries (Zengzhu *et al.*, 1999; Fotedar *et al.*, 2007a; Zeehaida *et al.*, 2008). Thus, there is an urgent need to improve the diagnostic techniques for the detection of intestinal and extraintestinal amoebiasis. Despite the prevalence of amoebiasis, there is still no available vaccine to prevent this deadly disease (Stanley, 2006). However, there have been progresses in research on potential vaccine candidates, the immunization route, and understanding of the protective immune responses against amoebiasis (Parija, 2011).

Nevertheless, amoebiasis is still a big challenge to public health in many regions, especially in the 'bottom billion' countries (Stanley, 2003). According to WHO (1997), the eradication of amoebiasis is essentially based on the improvement

of the quality of living conditions and education in the countries where the disease is prevalent (Salles *et al.*, 2003). Therefore, continuous improvement of the health programme, as well as monitoring and mapping the prevalence of amoebiasis is needed to achieve better prevention, diagnosis and treatment of the disease.

1.2 *Entamoeba histolytica*

1.2.1 Taxonomy

Traditionally, *Entamoeba* spp. have been placed in the phylum Sarcodina due to the presence of pseudopodia. However, based on molecular trees, Cavalier-Smith (2004) has classified *Entamoeba* spp. in the phylum of Amoebozoa, class of Archamoeba and are closely related to the slime mold. Humans are colonized by several species of *Entamoeba*, however most of them do not cause disease. *E. histolytica* is a well-known human pathogenic species that causes intestinal and extraintestinal amoebiasis. According to Pritt and Clark (2008), two non-pathogenic species of *Entamoeba* i.e. *E. dispar* and *E. moshkovskii* which show identical morphology but are genetically distinct, are responsible for most of the asymptomatic *Entamoeba* infections in humans. Therefore, the term amoebiasis is generally applied only to the disease caused by *E. histolytica* (WHO, 1997).

1.2.2 The biology of *Entamoeba histolytica*

E. histolytica is a unicellular eukaryotic organism that can be detected under the microscope in two different stages, i.e. cysts and trophozoites. Figure 1.1(a) shows the trophozoite ranges in size from 10-60 μM and is pleomorphic in shape. When isolated from the host, the cytoplasm of the trophozoite often shows ingested red blood cells (RBCs). It moves with the help of a single uroid (pseudopodium) and

mostly shows a single nucleus. Rough endoplasmic reticulum and Golgi bodies are not visible. Ribosomes are arranged in helices in the cytoplasm and a microtubular cytoskeletal network is not visible. The trophozoite is actively multiplying and highly motile in a human host. The pseudopods produced by an actively moving trophozoite are broad and finger-like, and the parasite generally moves in one direction at a time. *Entamoeba* trophozoites contain proteasomes in their cytoplasm, and these play an important role in cell differentiation and replication (Martínez-Palomo, 1982; Makioka *et al.*, 2002).


The shape of the cyst is round with diameter of 10-20 μM [Figure 1.1(b)]. It is an infective dormant stage and resistant to environmental stresses. A cyst initially has a single nucleus, while a mature cyst contains four nuclei. Each nucleus consists of a central karyosome surrounded by peripheral chromatin. Rod-like chromatoid bodies made of the assemblies of glycogen and ribosome may also be present, but they are more common in immature cysts.

Many of the enzyme metabolites which are produced by *E. histolytica* are believed to be originated from prokaryote, probably obtained via lateral gene transfer from bacteria (Yang *et al.*, 1994; Clark & Roger, 1995; Rosenthal *et al.*, 1997). The cyst cytoplasm has vacuoles with glycogen deposits which can be visible by permanent stains (Lohia, 2013). According to McLaughlin and Aley (1985), *E. histolytica* lacks glutathione and thus is unable to perform *de novo* purine synthesis, and this differentiates it from higher eukaryotes. In addition, the organization of *E. histolytica* gene is also different from other eukaryotes (Tannich *et al.*, 1992; Clark & Diamond, 1993). The ribosomal DNA (rDNA) episome map has been completely sequenced. The size of the circular DNA of *E. histolytica* is approximately 24.5 kb

a)




Trophozoite of *E. histolytica* or *E. dispar* stained with haematoxylin.




Trophozoite has a single nucleus, which has centrally placed karyosome and uniformly distributed peripheral chromatin.

b)



Cyst of *E. histolytica* or *E. dispar* stained with haematoxylin.

Cyst



Mature *E. histolytica* or *E. dispar* cyst has four nuclei that characteristically have centrally located karyosome and fine, uniformly distributed peripheral chromatin.

Figure 1.1 Morphological descriptions of *E. histolytica* or *E. dispar* (a) trophozoites and (b) cyst (CDC, 2010).

and has been shown to be useful in genotyping of enteric amoebae (Bhattacharya *et al.*, 1989).

E. histolytica, like *Giardia lamblia* is a type I amitochondriate protist, lacking both mitochondria and hydrogenosomes (Martin & Muller, 1998) [type II amitochondriate contains only hydrogenosomes]. These organisms lack features of aerobic eukaryotic metabolism, including the tricarboxylic acid (TCA) cycle and oxidative phosphorylation, and energy generation is primarily by substrate-level phosphorylation. In *E. histolytica*, an extended glycolysis pathway is present, in which pyruvate is converted to acetyl-coA by an enzyme called pyruvate ferredoxin oxidoreductase (PFOR). Subsequently, acetyl-coA can either be converted to acetate with ATP generation, or reduced to ethanol with regeneration of NAD (oxidized nicotinamide adenine dinucleotide) (Muller, 1998; Reeves, 1984; Haanstra *et al.*, 2008).

1.2.3 Life cycle

The *E. histolytica* life cycle is shown in Figure 1.2. The infection usually begins by ingestion of water or food that has been contaminated by *E. histolytica* cysts. Once the cysts reach the distal ileum, the intestinal secretions activate excystation whereby the quadrinucleated cysts develop into four motile trophozoites. Subsequently the amoebas undergo a round of nuclear division, followed by three rounds of cell division by binary fission that produces eight trophozoites. The trophozoites mostly colonize the cecal and sigmoidorectal regions of the large intestine, where they undergo another few rounds of divisions. The motile trophozoites adhere to and invade the cells of the gastrointestinal epithelium.

The invasion of colon is initiated by the parasite adherence and lysis of the colon epithelium, and this process is mediated by galactose and N-acetyl-D-galactosamine (Gal/GalNAc)-specific lectin of the trophozoite (Petri, 2002). Once the intestinal epithelium is invaded, trophozoites may spread to other parts of body, and most frequently end up in the liver, causing ALA. The factors that control invasion of the epithelial cells are most probably due to quorum sensing signalled by the amoebic Gal/GalNAc lectin, host innate and acquired immune responses and the interaction of the parasite with the intestinal bacterial flora (Tanyuksel & Petri, 2003). Some of the trophozoites may undergo encystation, in which the nucleus goes through two division processes to produce a quadrinucleate cyst, and may be excreted from the body through the stool. The factor responsible for the induction of encystation is unknown. López-Romero and Villagómez-Castro (1993), and Eichinger (1997) described that encystation is initiated when trophozoites round up into spherical forms, followed by formation of chromatoidal bodies in the cytoplasm. These bodies are ribosomal aggregates and when stained appear as elongated structures with rounded ends. Studies on *E. invadens* suggested that the process of encystation may be triggered by ligation of a surface galactose binding lectin on the surface of the protozoa (Eichinger, 2001; Stanley, 2003). Coppi *et al*, (2002) postulated that trophozoites aggregation in the mucin layer may also be a trigger for the encystation.

The cyst wall is smooth and refractile, and is made up of chitin. The maturation of cyst involves two rounds of nuclear replication, without any cell division. The cyst nucleus is morphologically similar to that of the trophozoite, however it becomes smaller with each division. Cysts can remain alive outside the




Figure 1.2 Life cycle of *E. histolytica* (CDC, 2010).

host for weeks or months, especially in damp conditions, but are rapidly destroyed at temperatures below -5°C and over 40°C (Fotedar *et al.*, 2007a).

The subsequent host may get infected when it ingests food or water contaminated with the cyst. Thus far, human and some non-human primates have been reported as the only natural hosts of *E. histolytica* (Stanley, 2003; Rivera *et al.*, 2010). Other *Entamoeba* spp., i.e. *E. hartmanii*, *E. coli* and *E. polecki*, can be differentiated from *E. histolytica*/*E. dispar*/*E. moshkovskii* by microscopy (Tanyuksel & Petri, 2003; Fotedar *et al.*, 2007a). A detailed description of the microscopic morphologies of the various *Entamoeba* spp. are described in section 1.8.1(a) [Figure 1.5 and Table 1.1] on pages 31-33.

1.3 Mode of transmission

In general, amoebiasis is transmitted via fecal-oral route, through the cysts ingestion from contaminated water or food (Tanyuksel & Petri, 2003). However, the parasite can also be transmitted among homosexual and institutionalized persons via oral–genital or oral–anal contact (Gatti *et al.*, 1995; Shelton, 2004; Moran *et al.*, 2005). Amoebiasis also spreads through immigrants who reside in endemic areas and travel to other places. Travellers returning from the endemic areas have been reported to have a high risk of infection. For instance, 47 of 469 individuals with diarrhoea were diagnosed as having amoebiasis after travelling to underdeveloped countries (Jelinek *et al.*, 1996). Another report showed that 0.3% of 2 700 German travellers had amoebiasis on their return from tropical areas (Weinke *et al.*, 1990). According to the Alberta Health and Wellness, Disease Control and Prevention report in year 2003, fewer than 80 cases were reported annually from 1995–2004; the infections were predominantly detected in individuals who have travelled to an underdeveloped area

(<http://www.health.alberta.ca/documents/Guidelines-Amoebiasis-2011>). Other than the above situations, *E. histolytica* is uncommonly transmitted in industrialized countries, and outbreaks are very rare in such places (Knobloch & Mannweiler, 1983; Salit *et al.*, 2009).

In addition, there is ambiguity regarding the zoonotic transmission of the amoeba from dogs, cats, rats, monkeys and probably pigs (Beaver *et al.*, 1984; Krauss *et al.*, 1997). The importance of primates in zoonotic infections was studied by Jackson *et al.* (1990). He investigated whether *E. histolytica* is a true zoonosis using zymodeme analysis. Although *E. histolytica* is commonly associated with animals, there is no report of sporadic transmission between humans and infected animals. In 2005, an amoebiasis outbreak was reported to occur among four chimpanzees kept in captivity at Sandal Kyarimi Park, Nigeria. Based on the laboratory results, cysts and trophozoites of *E. histolytica* were found in the stools of all the chimpanzees during the outbreak. The animals had most likely acquired the infection from the human attendants (Mbya & Nwosu, 2005).

Another study, using a molecular-based method, reported that *E. histolytica* or *E. dispar* infections were detected among wild rats in Malaysia (Lau *et al.*, 2014). Together, these studies showed the potential threats of zoonotic transmission as well as the importance of establishing preventive control measures.

1.4 Epidemiological studies on amoebiasis

Epidemiological studies of amoebiasis have been reported since 1925. Many were conducted to investigate the presence of *Entamoeba* spp. in certain regions such as South Africa, Bangladesh, Philippines, Brazil, Egypt and Greece (Haque *et al.*, 1997; Haque *et al.*, 1998a; Braga *et al.*, 1998; Rivera *et al.*, 1998; Gathiram & Jackson,

1987; Abd-Alla & Ravdin, 2002; Haque & Petri, 2006). However, reliable data were only obtained when researchers started to use molecular tools which were able to differentiate between species at the DNA level (Clark & Diamond, 1993; Tannich *et al.*, 1989; Burch *et al.*, 1991). This was because microscopic examination is unable to distinguish among morphologies of *E. histolytica*, *E. dispar* and *E. moshkovskii* (Baron, 1996).

1.4.1 Intestinal amoebiasis

A study by Nath *et al.* (2015) using species specific PCR assay found that the prevalence rate of *E. histolytica* at community health care units and hospitals in a North East Indian population was 13.7%. Ximenez (2009) reported that the incident rate of intestinal amoebiasis in Mexico between 1995-2000 was in range of 1 000 to 5 000 cases per 100 000 inhabitants. An investigation of *Entamoeba* infection in Sudan, using PCR, reported that the highest rate of infection by *E. histolytica*, among microscopic-positive individuals who attended the University of Medical Sciences and Technology (UMST) hospital was 54.1% (Saeed *et al.*, 2011). The study also showed that prevalence of co-infection with *E. histolytica* and *E. dispar* was 5.1%, similar to the co-occurrence rate of *E. histolytica* and *E. dispar* in the stool samples in Bangladesh as reported by Haque *et al.* (1998a). Meanwhile, the prevalence of *E. histolytica* infection among preschool children living in Mirpur district of Dhaka, Bangladesh was reported to be 4.2%, as determined by *E. histolytica* II ELISA kit (Haque *et al.* 2006). A survey on the prevalence of intestinal parasites among the expatriates and native Emirati people in UAE showed that protozoan infections (92.2%) were higher than helminthic infections (7.8%). Among the former, *E. histolytica*/*E. dispar* (71.8%) and *G. lamblia* (17.5%) were the most common

parasites (ElBakri *et al.*, 2013). In Pakistan the prevalence of *E. histolytica*/*E. dispar*, as detected using formalin-ether concentration technique (FECT) was reported to be 8.6% (Tasawar *et al.*, 2013).

Using PCR assay, Al-Hindi *et al.* (2005) reported higher prevalence rates of *E. histolytica* (69.6%) than *E. dispar* (22.8%) among children in Gaza, Palestine. In a town near Abidjan, Ivory Coast, PCR analysis showed that the ratio of *E. histolytica* to *E. dispar* was 1:46 among microscopically positive samples (Heckendorn *et al.*, 2002). A study was conducted by Samie *et al.* (2007) on stool samples in South Africa using nested PCR and ELISA. The results showed that *E. histolytica* was detected in 18.8% and 2.1% of samples from public hospitals and primary schools respectively. Meanwhile *E. dispar* was detected in 25.3 % and 8.5% of samples from public hospitals and primary schools respectively. In a clinical setting in Sweden, Lebbad *et al.* (2005) found that 79.7% (165/207) and 4.8% of patients' stools were PCR-positive for *E. dispar* and *E. histolytica* respectively. In Iran, Mojarad *et al.* (2010) reported that among 3 825 stool samples, 3.5%, 91.4% and 3.5% were PCR-positive for *E. histolytica*, *E. dispar* and *E. moshkovskii*, respectively. Another study conducted among prisoners and primary-school children in Ethiopia showed that real-time PCR detected *E. dispar* in 91.5% (195/213) of microscopy positive samples (Kebede *et al.*, 2004). In Australia, among microscopy positive stool samples at St. Vincent's Hospital, PCR analysis showed that 70.8% and 50% were positive for the non-pathogenic *E. dispar* and *E. moshkovskii* respectively (Fotedar *et al.*, 2007b).

Meanwhile in Malaysia, real-time PCR on microscopy positive stool samples of Orang Asli (aborigines) showed prevalence rates of 13.2% *E. histolytica* and 9.9% *E. dispar* (Lau *et al.*, 2013). On the other hand, a cross sectional study of 500 Orang

Asli stool samples using single-round PCR assay showed a high prevalence of *E. dispar* (13.4%), as compared to *E. histolytica* (3.2%) and *E. moshkovskii* (1%) (Anuar *et al.*, 2012). In contrast, using nested PCR, Ngui *et al.* (2012) and Noor Azian *et al.* (2007) reported a high prevalence of 76% and 13.2% *E. histolytica* respectively among the aborigine community. In the year 2004, an amoebiasis outbreak was reported at aborigine villages in the Cameron Highlands, and nested PCR assays were performed on stool samples collected from individuals with diarrhoea. The results showed that *E. histolytica* and *E. dispar* were detected in 13.2% and 5.6% of the stool samples (n=28) respectively (Noor Azian *et al.*, 2006). A study among the Malaysian urban population in Kuala Lumpur demonstrated a low prevalence (0.4%) of *E. histolytica/E. dispar* was reported by Jamaiah and Rohela (2005).

According to Hung *et al.* (2008), in developed countries amoebiasis is more prevalent in older individuals among homosexual men and institutionalized persons. Studies in Japan have shown that *E. histolytica* was more than *E. dispar* among male homosexuals (Takeuchi *et al.*, 1990; Ohnishi *et al.*, 2004). Many researchers from Taiwan, Japan and Korea reported an increasing number of HIV-infected homosexuals who were diagnosed with invasive amoebiasis. Approximately 80% of amoebiasis cases in Japan occurred among homosexuals and most of them were co-infected with HIV and syphilis (Takeuchi *et al.*, 1987; Ohnishi *et al.*, 2004; Nozaki *et al.*, 2006). This finding is in concordance with a study by Hung *et al.* (2005) in Taiwan which showed that HIV-infected individuals were at increased risk for invasive amoebiasis, and showed high frequency of increased antibody titers and *E. histolytica* colonization of the intestine.

After reviewing all the published reports from 1929 to 1997, Acuna-Soto *et al.* (2000) reported that the male to female ratios for invasive intestinal amoebiasis and asymptomatic carriage were 3.2:1 and 1:1, respectively. Most of the asymptomatic carriage infections were due to *E. dispar*. However, according to Rivera *et al.* (1998) who studied 14 communities in the northern Philippines, there was no significant difference in gender distributions of *E. histolytica*. The same observation has also been made in other community-based studies (Okafor & Azubike, 1992; Magambo *et al.*, 1998; Hamze *et al.*, 2004; Sharma *et al.*, 2004; Tasawar *et al.*, 2010). Nevertheless, several hospital-based studies recorded gender preference of *E. histolytica* infection. For example, Ozyurt *et al.* (2007) reported *E. histolytica* in 67% males as compared to 33% females among patients at a hospital in Turkey. The study concurred with Ohnishi and Murata (1997), who found that 26 out of 28 males and no females were infected with *E. histolytica* in the east-southeast area of Tokyo, Japan. Conversely, Ozgümüş and Efe (2007) reported that 64% of the attendees of a healthcare centre in Turkey who were infected with *E. histolytica* were females (16/25). Gender comparison of *E. histolytica* infection in Pakistan (hospital-based study) showed higher prevalence rate in females (31.5%) than males (19.6%) (Ejaz *et al.*, 2011).

The non-pathogenic species, *E. moshkovskii* has also been reported in several countries though is usually not associated with disease; this include India, Bangladesh, Iran, Australia, Turkey, Malaysia, Tanzania and South Africa (Parija & Khairnar, 2005; Solaymani-Mohammadi *et al.*, 2006; Hooshyar *et al.*, 2012; Fotedar *et al.*, 2008; Anuar *et al.*, 2012; Beck *et al.*, 2002; Beck *et al.*, 2008).

1.4.2 Extraintestinal amoebiasis

With regard to ALA, it is commonly present with an acute and sub-acute history of fever and right upper quadrant pain, although in 20% to 50% of cases showed a more chronic presentation with a protracted history of diarrhoea, weight loss and abdominal pain (Ralph & Kempston, 2012). In developed countries, patients who present with ALA have usually travelled to one of the endemic regions (Salles *et al.*, 2003). Knobloch and Manweiler (1983) found that 35% of travellers spent fewer than six weeks in an endemic area before developing ALA. A study conducted in the province of Thua Thien Hue, in Central Vietnam, reported 2 031 cases of ALA between 1990 and 1998, suggesting that the annual incidence of ALA was at least 21 per 100 000 individuals (Blessman *et al.*, 2002a; Blessman *et al.*, 2002b). The risk of acquiring ALA was higher in summer and was age and gender dependent; whereby 95 % of the cases were adults, and the majority of whom were males (80%). Meanwhile, in a retrospective analysis over a 5 year period, in the medical emergency of a Northern India Hospital, 86 cases of ALA were reported, with a mortality rate of 8.5% (Sharma *et al.*, 2010).

Based on a 10-year retrospective study from 1998 to 2008, 38 cases of ALA were reported in many hospitals in Malaysia (Jamaiah & Shektar, 1999). In a recent 15 years (from 1999 to 2014) retrospective study, among 6 867 ill returning Israeli travelers, 53 were diagnosed with all forms of amoebiasis (0.77%), and the rate of ALA among all cases of amoebiasis was 26% (14/53). In addition, twelve of the 14 cases (86%) had an exposure in the Indian subcontinent (Lachish *et al.*, 2016). According to Zeehaida *et al.* (2008), 58 cases of suspected ALA infection were clinically diagnosed at the Hospital Universiti Sains Malaysia (HUSM), with 72.4% being seropositive for the presence of anti-*E. histolytica* antibodies. In another study,

approximately 76.7% of the 30 liver abscess cases at HUSM were found positive for the presence of *E. histolytica* DNA in the pus aspirates samples during 2008 and 2009 (Othman *et al.*, 2010). ALA was also reported to affect mostly male patients between the age of 18 and 50, in whom rates were 3 to 20 times higher between populations (De-Bakey & Ochsner, 1951; Abuabara *et al.*, 1982; Katzenstein *et al.*, 1982; Thompson *et al.*, 1985; Barnes *et al.*, 1987; Acuna-Soto *et al.*, 2000). Other than that, ALA was also documented to increase in patients with altered cell-mediated immunity such as HIV infection, which might increase the likelihood of *E. histolytica* infection causing liver disease (Park *et al.*, 2007).

1.5 Clinical manifestation of amoebiasis

Amoebiasis produces a varied range of clinical manifestations. Hematologic spread of *E. histolytica* infection can lead to intestinal colonization, colitis as well as extraintestinal amoebiasis. The disease presentations vary in different populations, and depend on factors such as living standard, sanitary condition and nutritional status (Petri & Singh, 1999).

1.5.1 Asymptomatic carrier

The asymptomatic carriers of amoebiasis are individuals with no signs and symptoms of either intestinal or extraintestinal amoebiasis, but with the presence of *E. histolytica* trophozoites or cysts in their intestines or stools. Cysts are usually detected, though trophozoites with ingested red blood cells are rarely seen. Asymptomatic individuals should be treated because they are sources of transmission and the disease can develop and progress into an invasive disease. However, often there is spontaneous resolution of the infection, without disease development (Haque *et al.*, 2001; Blessmann & Tannich, 2002; Blessmann *et al.*, 2006)

1.5.2 Intestinal Amoebiasis

According to Faust *et al.* (1970), within a year, 4-10% of individuals who are asymptomatic may develop the disease. Symptomatic patients usually suffer from intestinal amoebiasis and may present as amoebic colitis or amoebic dysentery. Typical symptoms of amoebic colitis include gradual onset of abdominal pain (over several weeks), tenderness, diarrhoea, fever and bloody stools. The diarrhoea may result in 10 or more bowel movements in a day (Reed, 2000). Commonly, multiple and small volume mucoid stools are observed, however profuse and watery diarrhoea may also be seen (Adams & McLeod, 1977). In addition, bleeding per rectum without diarrhoea may be observed, particularly in children (Ralph & Kempston, 2012). It is surprising that only a small proportion of patients with amoebic colitis have fever (8-38%) (Lewis & Antia, 1970; Adams & McLeod, 1977; Abd-Alla & Ravdin, 2002).

However, it is crucial, albeit difficult to distinguish symptoms of infectious and non-infectious intestinal diseases. Examples of the latter are inflammatory bowel disease, ischemic colitis, diverticulitis, and arteriovenous malformations. These could also be confused with bacterial dysenteries that are common in tropical and subtropical areas such as shigellosis, campylobacteriosis, salmonellosis, and enteropathogenic *Escherichia coli* infection (Haque *et al.*, 1997; Sakata *et al.*, 2001). Moreover, the clinical presentation of amoebic colitis can also be confused with Crohn's disease (Baron, 1996).

Occasionally, individuals may develop fulminant amoebic colitis, with profuse bloody diarrhoea, leucocytosis, fever, and severe abdominal pain, and this condition has been reported to result in mortality rate of more than 40% (Stanley, 2003). Toxic megacolon occurs in approximately 0.5% amoebic colitis cases, and is

generally associated with the use of corticosteroids. Since patients with toxic megacolon commonly do not respond to anti-amoebic therapy alone, early recognition and surgical intervention are important. Ameboma can occur as a result of the formation of annular colonic granulation tissue (single or multiple sites) in the cecum or ascending colon. In addition, cutaneous amoebiasis (Mhlanga *et al.*, 1992; Magaña-Garcia & Arista-Viveros, 1993) and rectovaginal fistulas (Lysy *et al.*, 1991) may also be a result of intestinal amoebiasis. Figure 1.3 shows some microscopic images of the above.




Figure 1.3 Microscopic observations of invasive intestinal amoebiasis, (a) Intestinal flask-shaped ulcers observed through rectosigmoidoscopy examination; arrows indicate the colonic ulcers. (b) Large bowel necropsy specimen from a case of fulminant amoebic colitis; arrows indicate hemorrhagic ulcers and intestinal mucosa necrosis. (c) Necropsy specimen of liver abscesses; arrows indicate the three large abscesses. (d) Intestinal biopsy obtained from the edge of flask-shaped ulcer where large numbers of trophozoites (HE and PAS stained, 60x) are clearly visible. (e) Biopsy obtained from the edge of ALA (HE and PAS stained, 20x); trophozoites, hepatocytes, and the large number of inflammatory cells are indicated by arrows (Ximenez *et al.*, 2011).